In the drug screening phase, the MSC-PDO-PBMC microfluidic chip exhibited a more predictable response to PD-L1-targeted therapies, such as Atezolizumab, faithfully recapitulating the tumor microenvironment and immune interactions. This evidence concerns the gene CD274 and neoplasm.